Search for novel neuraminidase inhibitors: Design, synthesis and interaction of oseltamivir derivatives with model membrane using docking, NMR and DSC methods

Biochimica et Biophysica Acta - Biomembranes

Volumn 1788, Issue 9, 2009, Pages 1740-1751

  D'Souza, Charlotte ^a   Kanyalkar, Meena ^a   Joshi, Mamata ^b   Coutinho, Evans ^c   Srivastava, Sudha ^b  

^a PRIN K M KUNDNANI COLLEGE OF PHARMACY   (India)

^b TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

^c BOMBAY COLLEGE OF PHARMACY   (India)

Author keywords

Differential scanning calorimeter; Docking; Model membrane; Neuraminidase; Nuclear magnetic resonance; Oseltamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ACETYLOSELTAMIVIR; BENZYLOSELTAMIVIR; DIPALMITOYLPHOSPHATIDYLCHOLINE; GLYCYLOSELTAMIVIR; OSELTAMIVIR; PROLYLOSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR;

ARTICLE; ARTIFICIAL MEMBRANE; BILAYER MEMBRANE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; INFLUENZA VIRUS A H5N1; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANTIVIRAL AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CATALYTIC DOMAIN; COMPUTER SIMULATION; DRUG DESIGN; INFLUENZA A VIRUS, H5N1 SUBTYPE; LIPID BILAYERS; LIPOSOMES; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, MOLECULAR; NEURAMINIDASE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; OSELTAMIVIR;

ORTHOMYXOVIRIDAE;

EID: 68949172175     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2009.04.014     Document Type: Article

References (53)

1. Beigel J.H., et al. Avian influenza A (H5N1) infection in humans. N. Engl. J. Med. 353 (2005) 1374-1385
2. Ghafar A.N.A. Update on avian influenza A (H5N1) virus infection in humans. N. Engl. J. Med. 358 (2008) 261-273
3. Colman P.M., Tulip W.R., Varghese J.N., Tulloch P.A., Baker A.T., Laver W.G., Air G.M., and Webster R.G. Three-dimensional structures of influenza virus neuraminidase-antibody complexes. Philos. Trans. R. Soc. Lond. B Biol. Sci. 323 (1989) 511-518
4. World Health Organization. A revision of the system of nomenclature for influenza viruses: a WHO memorandum. Bull. World Health Organ. 58 (1980) 585-591
5. Liu C., Eichelberger M.C., Compans R.W., and Air G.M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol. 69 (1995) 1099-1106
6. Clercq E.D. Antiviral agents active against influenza A virus. Nature 5 (2006) 1015-1025
7. Lew W., Chen X., and Kim C.U. Discovery and development of GS 4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 7 (2000) 663-672
8. Dunn C.J., and Goa K.L. Zanamivir: a review of its use in influenza. Drugs 58 (1999) 761-784
9. Oliyai R., Yuan L., Dahl T.C., Swaminathan S., Wang K., and Lee W.A. Biexponential decomposition of a neuraminidase inhibitor prodrug (GS-4104) in aqueous solution. Pharm. Res. 15 (1998) 1300-1304
10. Mendel D.B., Tai C.Y., Escarpe P.A., Li W., Sidwell R.W., Huffman J.H., Sweet C., Jakeman K.J., Merson J., Lacy S.A., Lew W., Williams M.A., Zhang L., Chen M.S., Bischofberger N., and Kim C.U. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42 (1998) 640-646
11. Li W., Escape P.A., Eisenberg E.J., Cundy K.C., Sweet C., Jakeman K.J., Merson J., Lew W., Williams M., Zhang L., Kim C.U., Bischofberger N., Chen M.S., and Mendel D.B. Identification of GS-4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS-4071. Antimicrob. Agents Chemother. 42 (1998) 647-653
12. McKimm-Breschkin J.L. Resistance of influenza viruses to neuraminidase inhibitors - a review. Antiviral Res. 47 (2000) 1-17
13. Moscona A. Oseltamivir resistance - disabling our influenza defenses. N. Engl. J. Med. 353 (2005) 2633-2636
14. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353 (2005) 1363-1373
15. Chou K.C. Review: structural bioinformatics and its impact to biomedical science. Curr. Med. Chem. 11 (2004) 2105-2134
16. D'Souza C., Kanyalkar M., Joshi M., Coutinho E., and Srivastava S. Probing molecular level interaction of oseltamivir with H5N1-NA and model membranes by molecular docking, multinuclear NMR and DSC methods. Biochim. Biophys. Acta 1788 (2009) 484-494
17. Greengard O., Poltoratskaia N., Leikina E., Zimmerberg J., and Moscona A. The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. J. Virol. 74 (2000) 11108-11114
18. Porotto M., Murrell M., Greengard O., Lawerence M.C., Mckimm-Breschkin J.L., and Moscona A. Inhibition of parainfluenza virus type 3 and Newcastle disease virus hemagglutinin neuraminidase receptor binding: effect of receptor avidity and steric hindrance at the inhibitor binding sites. J. Virol. 78 (2004) 13911-13919
19. Santos J.S., Lee D., and Ramamoorthy A. Effects of antidepressants on the conformation of phospholipid headgroups studied by solid-state NMR. Magn. Reson. Chem. 42 (2004) 105-114
20. Aue W.P., Bartholdi E., and Ernst R.R. Two-dimensional spectroscopy - application to nuclear magnetic resonance. J. Chem. Phys. 64 (1976) 2229-2246
21. Jeener J., Meier B.H., Bachmann P., and Ernst R.R. Investigation of exchange processes by two-dimensional NMR spectroscopy. J. Chem. Phys. 71 (1979) 4546-4553
22. Braunschweiler L., and Ernst R.R. Coherence transfer by isotropic mixing: application to proton correlation spectroscopy. J. Magn. Reson. 53 (1983) 521-528
23. Bothner-By A.A., Stephens R.L., Lee J., Waren C.D., and Jeanloz R.W. Structure determination of a tetrasaccharide: transient nuclear Overhauser effects in the rotating frame. J. Am. Chem. Soc. 106 (1984) 811-813
24. Kornberg R.D., and Mc Connel H.M. Inside-outside transitions of phospholipids in vesicle membranes. Biochemistry 10 (1971) 1111-1120
25. Cheng H.Y., Randall C.S., Holl W.W., Constantinides P.P., Yue T.L., and Feuerstein G.Z. Carvedilol-liposome interaction: evidence for strong association with the hydrophobic region of the lipid bilayers. Biochim. Biophys. Acta 1284 (1996) 20-28
26. Discovery Studio version 2.0, Accelrys Inc., USA.
27. GOLD 3.0.1 CCDC Ltd., UK.
28. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., and Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 (2006) 45-49
29. 13C spectra using DEPT and a quaternary-only sequence. J. Mag. Res. 53 (1983) 272-296
30. 15N resonance assignments of the N-terminal SH3 domain of drk in folded and unfolded states using enhanced-sensitivity pulsed field gradient NMR techniques. J. Biomol. NMR 4 (1994) 845-858
31. Lambros M.P., Sheu E., Lin J.S., and Pereira H.A. Interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes. Biochim. Biophys. Acta 1329 (1997) 285-290
32. Perkins W.R., Li X., Slater J.L., Harman P.A., Ahl P.L., Minchey S.R., Gruner S.M., and Janoff A.S. Solute-induced shift of phase transition temperature in di-saturated PC liposomes: adoption of ripple phase creates osmotic stre. Biochim. Biophys. Acta 1327 (1997) 41-51
33. Neumann J.M., Zachowski A., Tran-Dinh S., and Devaux P.F. High resolution proton magnetic resonance of sonicated phospholipids. Eur. Biophys J. 11 (1985) 219-223
34. 13C Nuclear magnetic relaxation times and models for chain motion in lecithin vesicles. FEBS Lett. 23 (1972) 203-207
35. 31P-NMR study on the properties of palmitoyllysophosphatidylcholine in bilayers with gramicidin, cholesterol and dipalmitoylphosphatidylcholine. Biochim. Biophys. Acta 854 (1986) 133-142
36. Chary K.V.R., and Govil G. NMR in Biological Systems, from Molecules to Humans (2008), Springer, The Netherlands 291-315
37. Srivastava S., Phadke R.S., and Govil G. Role of tryptophan in inducing polymorphic phase formation in lipid dispersion. Ind. J. Biochem. Biophys. 25 (1988) 283-286
38. Thennarasu S., Lee D., Poona A., Kawulka K.E., Vederas J.o.h.n.C., and Ramamoorthy A. Membrane permeabilization, orientation, and antimicrobial mechanism of subtilosin A. Chem. Phys. Lipids 137 (2005) 38-51
39. Ramamoorthy A., Thennarasu S., Tan A., Lee D., Clayberger C., and Krensky A.M. Cell selectivity correlates with membrane-specific interactions: a case study on the antimicrobial peptide G15 derived from granulysin. Biochim. Biophys. Acta 1758 (2006) 154-163
40. Epand R.M., Epand R.F., and McKenzie R.C. Effects of viral chemotherapeutic agents on membrane properties, Studies of cyclosporin A, benzyloxycarbonyl-d-Phe-l-Phe-Gly and amantadine. J. Biol. Chem. 262 (1987) 1526-1529
41. Veiga M.P., Arrondo J.L.R., Goni F.M., and Alonso A. Ceramides in phospholipid membranes: effects on bilayer stability and transition to nonlamellar phases. Biophys. J. 76 (1999) 342-350
42. Almgren M., Edwards K., and Karlsson G. Cryo transmission electron microscopy of liposomes and related structures. Colloids Surfaces A: Physicochem. Eng. Asp. 174 (2000) 3-21
43. Chakraborty H., Chakraborty P.K., Raha S., Mandal P.C., and Sarkar M. Interaction of piroxicam with mitochondrial membrane and cytochrome c. Biochim. Biophys. Acta 1768 (2007) 1138-1146
44. Kohn A. Permeability to inhibitors of protein synthesis in virus infected cells. Adv. Viral Res. 24 (1979) 223-276
45. White J., Keilian M., and Helenius A. Low pH deforms the influenza virus envelope. Q. Rev. Biophys. 16 (1983) 151-195
46. Young J.D.E., Young G.P.H., Cohn Z.A., and Lenard J. Mutational analysis of receptor interaction and membrane fusion activity of sindbis virus. Virology 128 (1983) 186-194
47. Colman P.M., Hoyne P.A., and Lawrence M.C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J. Virol. 67 (1993) 2972-2980
48. Wang G.T., Chen Y., Wang S., Gentles R., Sowin T., Kati W., Muchmore S., Giranda V., Stewart K., Sham H., Kempf D., and Laver W.G. Design, synthesis and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. J. Med. Chem. 44 (2001) 1192-1201
49. McElhaney R.N. Differential scanning calorimetric studies of lipid-protein interactions in model membrane systems. Biochim. Biophys. Acta 864 (1986) 361-421
50. Epand R.F., Ramamoorthy A., and Epand R.M. Membrane lipid composition and the interaction of pardaxin: the role of cholesterol. Protein and Peptide Lett. 13 (2006) 1-5
51. Cater B.R., Chapman D., Hawes S.M., and Saville J. Lipid phase transitions and drug interactions. Biochim. Biophys. Acta 363 (1974) 54-69
52. Epand R.M. Virus replication inhibitory peptide inhibits the conversion of phospholipid bilayers to the hexagonal phase. Biosci. Rep. 6 (1986) 647-653
53. McKenzie R.C., Epand R.M., and Johnson D.C. Cyclosporine A inhibits herpes simplex virus-induced cell fusion but not virus penetration into cells. Virology 159 (1987) 1-9